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Abstract
Purpose: Approximately 20 % of tumors have the opportunity to be resected in patients with hepatocellar carcinoma (HCC) and
their prognoses were acceptable. For the unrespectable HCC, however, the outcomes were rather poor because the specialty of
the tumor blood supply and the tumor was insensitive to the chemotherapy drug. The objective of this study was to find sensi-
tive drugs for individual patients and determine the safety and antitumor activity of hepatic intra-arterial and portal vein infu-
sion chemotherapy. Methods: A total of 120 patients with the mean patient age of 56 years and with unresectable HCC were
randomly divided into experimental group and control group. The experiment group was infused through an intra-arterial and
portal vein catheter 3 different drugs were chosen by the results of drug sensitive test, whereas the control group was treated
for TACE. The changes in tumor-size and AFP, two-step operation rate, survival rate, and complications were observed in these
patients. Results: The tumor size reduced in 28 (47.6%) cases, stabilized in 14 (23.3%) cases, and progressed in 18 (30%) cases in
experimental group as measured by CT or MRI after six chemotherapy cycles, whereas the corresponding data was 17 (28.5%)
cases, 7 (11.5%) cases and 36 (60%) cases in the control group (P < 0.05). The AFP was declined in 51 cases in experimental
group and in 30 cases in control group (P < 0.05). In the experimental group, the median follow-up time was 21 months; the
overall survival rates (OS) of 6 months, 12 months, and 18 months were 86%, 72%, and 65%, respectively. In the control group,
the median follow-up time was 16 months; the OS rates of 6 months and 12 months were 58% and 40%, respectively. Six pa-
tients in the experimental group and 3 patients in the control group had two-step operation. There was no severe incidence of
complications in both groups. In the experimental group, 2 (3%) patients had wound infection, 8 cases had the chemotherapy
relative diarrhea, and 18 (30%) cases had grade Ⅰ or Ⅱ bone marrow suppression. In the control group, the chemotherapy
relative diarrheas were 15 (25%) cases and grade Ⅰ or Ⅱ bone marrow suppression were 33 (55%) cases. Conclusion: The
artery and portal vein pump transfusion chemotherapy guided by drug sensitive test was efficient for HCC treatment. The pa-
tients can get longer OS and lower complication incidence.
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Introduction
Because the liver tumors are not easily found, only less than
20% of the primary liver cancers have the opportunity to be
surgically removed. Treatment of hepatic artery chemother-
apy embolism (TACE) is one of the therapeutics available to
cure the advanced stage unresectable liver cancer; however,
the effective rate is about 30% to 40%. Research showed that
primary liver cancers have hepatic artery and portal vein
dual blood supplies: blood vessel in the center of the tumor is
mainly composed of hepatic artery whereas the peripheral
part is mainly composed of portal vein. The cancer cells tend
to invade the intrahepatic vascular, especially into the portal
system, which promote the portal venous embolism and
Corresponding author: Shaozhong Wei; Cancer Hospital of Wu-
han University, Zhuodaoquan South Road, Hongshan district,
Wuhan, 430079, China.
Cite this article as:
Wu D, Wei S, Luo C, Wu X, Feng Y, Zhang F, Nie L, Xia X. Clini-
cal study on the sensitivity test guided hepato-arterial/portal -vein
chemotherapy in patients with unresectable hepatocellar carci-
noma. Int J Cancer Ther Oncol 2014; 2(2):02029.
DOI: 10.14319/ijcto.0202.9
2 Wu et al.: Sensitivity test guided hepato-arterial/portal-vein chemotherapy International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Wu et al. ISSN 2330-4049
have negative effects of conventional TACE. In order to im-
prove the efficiency to cure primary liver cancer, scholars
developed the hepatic artery/portal vein pump chemothera-
py (HA/PVPC).1 However, liver cancer is not aeschynome-
nous to chemotherapy. To improve the efficiency of indi-
vidual patiens to HA/PVPC, we used individualized drug to
patients based on their sensitive tests (MTT) and perfused
the drugs through transartery and portal vein dual channel.
We aimed to increase the regional drug concentration and
improve the tumor susceptibility to drugs, thus improving
the efficiency of liver cancer treatment.
Methods and Materials
Patients
Between October, 2010 and October, 2005, 120 cases of un-
resectable HCC were randomly divided into experimental
group and control group. 60 patients in the experimental
group were enrolled to determine the safety and antitumor
activity of hepatic intra-arterial and portal vein infusion
chemotherapy; another 60 patients were enrolled in the
control group. The clinical protocol was reviewed and ap-
proved by the Institutional Review Board of the Hubei Can-
cer Hospital. All study participants provided written in-
formed consent prior to therapy. Eligible study participants
were chosen according to the following inclusion criteria:
 Liver function test was Child A-B grade;
 Tumor cannot be resected;
 Eastern Cooperative Oncology Group performance
status was 0 or 1;
 Total bilirubin concentration was ≤1.0 mg/dL;
 Serum creatinine concentration was ≤1.5 mg/dL;
 Prothrombin time was <13 seconds; activated par-
tial thromboplastin time was < 30 seconds; and
 Complete blood count was normal. All of the pa-
tients before treatment did not use any antitumor
drugs.
Preparation of tumor cells
Sampling: Specimens of primary liver cancer tissue was ob-
tained from surgical biopsy, placed into RPMI 1640 culture
medium which contained streptomycin (100 U/ml) and pen-
icillin streptomycin (100 mg/ml) within 10 minutes after
shearing, preserved in 4 ℃ refrigerator, and processed as
described below within 4 hours.
Processing samples: Tissue blocks were placed in a petridish,
cut off blood clots and unused tissues, rinsed with hanks
solution twice, and then cut into 1 mm3 tissue blocks.
Isolating cells: We crushed the small tissue blocks gently by
repeatly passing through a syringe needle, The tissue ho-
mogenate was filtered through 4 layers of gauze followed by
centrifugation in low speed centrifuge machine (800 rpm, 5
min) twice.
Cell culture
Cells were cultured in RPMI 1640 (Gibco, Invitrogen) sup-
plemented with 10% (v/v) heat inactivated fetal bovine se-
rum (Gibco, Invitrogen) and 1% (v/v) antimicotic antibiotic
(Gibco, Invitrogen)at 37°C under a 5% CO2 atmosphere. The
cells adhered to the wall of the culture flasks after 48 hours.
After 4 days of incubation, the cell concentration was ad-
justed to (2 to 5) × 105/ml.
Cell viability assay (MTT assay)
100 ul of liver cancer cells were seeded on 96-well plates.
For the cells in the experimental group, seven chemotherapy
drugs (5-FU/ DDP/ ADM/ MMC/ HCPT/ LOHP/ GEM) were
individually added to the cells in triplicate at a concentration
ten times higher than that used clinically. No drug was add-
ed to the cells in control group. 1640 medium was used as a
blank control. Cells were cultured for 48 hours. Then the
cells were added 20 ml of MTT (5 mg/ml) and continually
cultured for 4 hours before replacing culture medium with
dimethyl sulfoxide (100 μL/well) to terminate the reaction.
The cells were finally vibrated for 5 minutes and the ab-
sorbance (value A) was measured by a micro plate reader at a
wavelength of 570 nm.
Drugs inhibition rate = [1 - (average A value in drug treat-
ment wells / average A value in negative control wells)]. A
rate value > 50% is defined as hypersensitivity; 30% to 50%
as mild sensitive; < 30% as drug resistance.
Sensitive rate (%) = (sensitive cases / total cases of the group)
× 100%
Clinical experiment
All patients in the experimental group underwent angio-
graphic placement of two catheters for hepato-artory and
portal vein. We obtained the hepatic tumor biopsy for
pathological diagnosis and then The Bard Access Ports (de-
tailed information showed below) were inserted into the
right gastro-omental artery and the right gastro-omental
vein to establish regional chemotherapy channels. Seven
chemotherapy drugs were used as the experimental drugs
(detailed information showed below). We infused each indi-
vidual in the experimental group by arterial and portal vein
pump 2 to 3 drugs which showed highest inhibition to the
cancers of the patient in our MTT test above. The drugs were
delivered equally in both channels. The regimen was re-
peated every 3 weeks unless there was a tumor progression,
withdrawal of consent, or occurrence of side effects, such as
bone marrow suppression, fulminant hepatitis, or other
greater than grade 3 toxicities, etc.
The control group patients underwent conventional TACE,
chemotherapy regimens were 5 - fluorouracil (1000mg/m2),
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mitomycin (10mg/m2) and cisplatin (100mg/m2), and with
iodipin embolization (scheme: MMC+DDP+5-Fu, iodipin
embolism).
The Bard Access Ports was purchased from West Amelia
Earhart Drive, Salt Lake City, Utah, USA. The cytotoxic
drugs included fluorouracil (5 FU, Tianjin Jinyao acid co.,
LTD), cisplatin (DDP, Yunnan Gejiu Supertrack
Bio-Pharmaceutical co.,LTD), adriamycin (ADM, Zhejiang
Hisun pharmaceutical co., LTD), mitomycin (MMC, Jiangsu
Henrui Medicine co.,LTD), hydroxy camptothecin (HCPT,
Hubei Huangshi Feiyun co., LTD), oxaliplatin (L-OHP,
Jiangsu Henrui Medicine co., LTD) and gemcitabine (GEM,
Hubei Halfsky pharmacy co., LTD)
Curative effect evaluation
Curative effect evaluation includes changes in serum tumor
marker AFP, tumor size and number, liver function, compli-
cations, and overall survival (OS).
Follow-up
Local therapeutic efficacy was evaluated by con-
trast-enhanced dynamic CT scanning after 2 courses of
chemotherapy or in the case of clinical suspicion for recur-
rence. Clinical tumor recurrence and response was assessed
according to the Response Evaluation Criteria in Solid Tu-
mors (RECIST version 1.0)2
Toxicity Assessment
Toxic effects were assessed during hospitalization of each
patient and at the patient baseline according to the National
Cancer Institute Common Toxicity Criteria guidelines, ver-
sion 2.0. CBCs. Liver function status, complications include
chemotherapy relative diarrhea andⅠ0 toⅡ0 bone marrow
stifled was inspected.
Statistical methods
Clinical responses between two groups were compared by
chi-square test. Kaplan-Meier analysis was applied to assess
OS, and the signiﬁcance of differences in survival curves was
determined by the log-rank test. OS was deﬁned as the peri-
od from the date of chemotherapy to the date of death. P <
0.05 was considered signiﬁcant for all analyses. The SPSS
software package, version 10.0 (SPSS Inc., Chicago, IL, USA)
was used for statistical analysis.
Results
Cell culture and drug sensitivity test
Primary tumor cells prepared from the specimens of primary
liver tumors obtained by biopsy turned into rapid logarith-
mic growth phase after cultured for 48 to 72 hours (Figure
1). After 4 days of incubation, chemotherapy drugs were
added at the top of the rapid logarithmic phase in the MTT
assay. As shown in Figures 2 and 3 and Table 1, different
drugs showed different inhibitions to the growth of cancer
cells from different patients. In addition, the cells were dis-
rupted and chromatin-mustered when the chemotherapy
drugs were added for 24 hours (Figure 4).












FIG. 1: Growth curve of liver cancer cells cultured in RPMI 1640
(Gibco, Invitrogen) supplemented with 10% (v/v) heat inactivated
fetal bovine serum and 1%(v/v) antimicotic antibiotic at 37°C under
a 5% CO2 atmosphere.
FIG. 2: Inhibition of liver cancer cell growth by chemotherapy drugs
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FIG. 3: Different inhibition ratios of 7 anti-cancer drugs to the growth of primary cancer cells. Different drugs have different anti-cancer sensi-
tivities to liver cancer cells.
FIG. 4: A. Cultured liver cancer cells began to stick the wall after cultured for 24 hours (×10); B. The cultured liver cancer cells clustered to-
gether for 48 hours (×20); C. The liver cancer cells were disrupted chromatin-mustered and began to die when the chemotherapy drugs were
added for 24 hours.
Clinical observation
120 cases of unresectable HCC were randomly divided into
experimental group and control group, the clinical patholog-
ical features of patients in both groups were not significant
different (Table 2). The mean patient age at the time of
treatment was 56 (range, 47 - 65) years. Bard Access Ports
were inserted into the right gastro-omental artery and the
right gastro-omental vein to establish regional chemotherapy
channels for all patients (Figure 5). Individual patients in the
experimental group were infused by arterial and portal vein
pump 3 drugs which showed highest inhibition to the can-
cers of the patient in our MTT test above, whereas the con-
trol group patients underwent TACE. In experimental group,
the tumor size reduced in 28 (47.6%) cases as measured by
CT or MRI after six chemotherapy cycles (Figure 6), stabi-
lized in 14 (23.3%) cases, and progressed in 18 (30%) cases.
The corresponding data was 17 (28.5%), 7(11.5%) and 36
(60%) cases in the control group (P < 0.05). The AFP was
declined in 51 cases in experimental group and in 30 cases in
control group (P < 0.05). 6 patients in the experimental
group and 3 in control group had the opportunity of
two-step operation (P < 0.05) (Table 3). There was no severe
incidence of complications in both groups. In the experi-
mental group, 2 (3%) cases of patients had wound infection,
8 cases had the chemotherapy relative diarrhea and 18 (30%)
cases hadⅠ0 toⅡ0 bone marrow stifled. In the control group,
The chemotherapy relative diarrhea was seen in 15 (25%)
cases andⅠ0 toⅡ0 bone marrow stifled was seen in 33 (55%)
cases (Table 4). For prognosis, in the experimental group, the
median follow-up time was 21 months, OS rates of 6 months,
12 months, 18 months were 86%, 72%, and 65% respective-
ly. In the control group, the median follow-up time was 16
months, OS rates of 6 months and 12 months were 58% and
40%, respectively (Figures 7).
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TABLE 2:Patient characteristics: patient and tumor features of the experimental group compared with control group
Experimental group Control group P-value
n 60 60
Age (Y)
Median (range) 56 (47-65) 55(46-64)
Male : Femal 53:7 11:1






Median (range) 9 (8 - 13.7) 9.3 (8.7 - 13.3)
Tumor number
1 23 37 > 0.05
≥2 21 39
Hepatitides
Hepatitis B 57 (95%) 58 (96.7%)
Hepatitis C 1 (1.7%) 1 (1.7%)
HepatitisB/C 0 (0%) 1 (1.7%)
Other 2 (3.3%) 0 (0%)
AFP (Log10ng/ml) 4.33 ± 2.52 4.18 ± 2.66
Child-pugh
A 38 (63.3%) 40 (66.7%)
B 22 (36.7%) 20 (33.3%)
C 0 (0%) 0 (0%)
Neoplasm
Single-tumor 6(10%) 4 (6.7%)
Multi-tumor 54(90%) 56 (93.3%)
FIG. 5: Bard Access Ports were inserted into the right gastro-omental artery and the right gastro-omental vein to establish regional chemother-
apy channels. A. Hepatic artery catheter was inserted into the blood vessel to liver tumor, the liver segment appeared blue after methylene blue
staining; B. Operation of insertaion of chemotherapy catheter; C. Artery images showing that the chemotherapy catheter was in the proper
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FIG. 6: The tumor size reduced in experimental group as measured by CT or MRI after six chemotherapy cycles. A. MRI showed that the tumor
was located in segments Ⅰand Ⅶ; B. The tumor size reduced and the blood supply decreased obviously after 6 cycles of chemotherapy; C.
Tumor located in segment Ⅶ and the cells growing into inferior vena cava (IVC) via right hepatic vein; D. The tumor size reduced and the
embolus in IVC and right hepatic vein disappeared after 6 cycles of chemotherapy.
TABLE 3: Clinical effect comparisons between experimental and control groups
Group n CT/MRI AFP           Two-step P-value
Reduce stabilize progress decrease rise/ stabilize operation (n)
experimental group 60 28      14      18 51 9 6 < 0.05
control  group 60 17       7      36 30 30          3
TABLE 4: Complications comparison between experimental and control groups
Group n wound infection abdominal pain hepatic failure myelosuppression P-value
experimental group 60 2 8 9 18 < 0.05
control  group 60 0 25 41 33
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FIG. 7: OS (Overall survival, months) comparison between experimental group and control group
Discussion
China is a country in which the morbidityof HCC is the
highest in the world, and the latest survey data showed that
the mortality rate of PHC is the highest in Hubei province.
Only less than 20% of the patients with PHC had the oppor-
tunity to be respected. Hepatic trans catheter arterial che-
moembolization (TACE) is currently the important therapy
of the middle and late stage of PHC patients with aeffective
rate of 30% ~ 40%. Research has showed that blood supply to
primary liver cancer is through both hepatic artery and por-
tal vein: the tumor center is mainly composed of hepatic
artery, and the peripheral part is mainly composed of portal
vein. The surrounding part is the most active part of the
cancer.3 HCC cells invade intrahepatic vascular extremely
common, especially the portal vein, taking shape of portal
vein embolus and giving rise to intrahepatic metastasis. This
is the reason why conventional TACE cannot achieve satis-
factory results.
The efficiency of cancer chemotherapy is decided by two
factors. The first is drug concentration in the tumor, and the
second is the drug effectiveness. Thus, it is important to im-
prove the drug efficiency. In the early 1950’s, Bierman first
reported hepatic artery perfusion chemotherapy for primary
liver cancer.4 Storer reported chemotherapy of hepatic neo-
plasms via umbilical portal vein in 1966 5 and other scholars
adopt the hepatic artery or portal vein catheter chemother-
apy for the sake of increasing the medicine concentration in
tumor, and achieved good efficiency. Here, we used drug
sensitivity test to select individualized drugs and perfused
the sensitive drugs to individual patients by hepatic artery
and portal vein channels, giving consideration to improve
the regional drug concentration and tumor susceptibility to
drugs and achieve high effectiveness of treatment of PHC.
Surgical resection is the preferred treatment for liver cancer,
but because of the low removal rate, the 5-year survival rate
of entire population of liver cancer is less than 5%.6 Molecu-
lar biology research proved that portal venous endothelial
cells have specific adhesion molecules which can bind the
various components in the blood, including cancer cells, to
promote the transfer and spread of tumor cells in the portal
vein.7,8 Clinical studies also demonstrated that hepatic artery
embolism chemotherapy and portal vein regional chemo-
therapy of hepatocellular carcinoma after surgical removal
can significantly decrease the rate of recurrence and metas-
tasis 9, and regional chemotherapy through hepatic artery is
safe and effective.10 Reports for colorectal cancer liver me-
tastasis in patients with arterial perfusion 5 - Fu can obtain
curative effect.11 With hepatic arterial infusion of fluoroura-
cil plus systemic irinotecan for unresectable hepatic metas-
tases from colorectal cancer, the patients have a response
rate of 72% and the median survival time is 49.8 months.12
Case reports also give us encouraging results. For patient
with gastric cancer and breast cancer which is metastasized
to liver, regional infusion chemotherapy gains curative ef-
fect.13, 14 In neuroendocrine carcinoma liver metastasis, re-
gional infusion chemotherapy is superior to system chemo-
therapy also.15 Primary hepatic carcinoma with Ⅲ/Ⅳ seg-
ment portal venous tumor emboli resort to hepatic artery
perfusion of cisplatin treatment after resection reached re-
lapse-free survival more than 1 year.16 Regional infusion
chemotherapy has better prospective than systemic chemo-
therapy of liver cancer, but there have been no correspond-
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ing treatment standards.17 Solid tumors metastatic to the
liver had received good prognosis with oxaliplatin, fluor-
ouracil and leucovorin infused from hepatic artery.18
For unresectable hepatocellular carcinoma, with continually
infusion of low dose fluorouracil and cisplatin by hepatic
artery, the liver tumor remission rate was 39%, and the me-
dian survival was 15.9 months.19 Tanaka’s research showed
that hepatic arterial infusion chemotherapy is a safe, effec-
tive method to liver cancer patients.20 The curative effect is
better and side-effect is lower with the chemotherapy cath-
eter infusion.21
The sensitivity of tumor cells to chemotherapy drugs can be
obtained by drug susceptibility test.22 Naitoh et al reported
after multicenter clinical trial that culture-drug sensitivi-
ty test predicts the outcome of patients undergoing chemo-
therapy for advanced gastric cancer and can be used as the
method to evaluate chemosensitivity.23 Taylor found that the
survival rate of the group of malignant tumor patients treat-
ed with sensitive drugs was obviously higher than that of the
drug resistant group and simple surgical treatment group.
This research suggested that the drug sensitivity test in vitro
guided individualized chemotherapy is effective.24
Another question debated is whether the result of the drug
susceptibility reaction in vitro is accordance with that in
vivo. In vitro results and the in vivo effectiveness may not
match exactly25, but recent studies have reported that 85.7%
consistency of susceptibility test in vitro and clinical obser-
vation.26 Kabeshima and Taylor's research showed that the
patients’ long-term survival rate was obviously higher in
drug-sensitive group than that of drug resistant group and
simple surgical group, this indicates that drug sensitivity test
in vitro can play an important role in directing the individu-
alized chemotherapy and improving the curative effect.24, 27
Thus, we carried out this study and our result is encouraging.
Compared with systemic chemotherapy, regional chemo-
therapy can have these advantages: (1) chemotherapy drug
concentration in the tumor increases significantly and makes
chemotherapy drug acts on the tumor tissues directly and
efficiency. (2) Along with the increase of the drug concen-
tration in the tumor, curative effect increase accordingly.
However, it is a critical factor of finding effective chemo-
therapy drugs for the patients and administrates these drugs
by regional catheters.
Seven anticancer drugs were chosen in our study for in vitro
drug sensitivity test in 60 cases of patients with unresectable
HCC. The results showed that the tumor inhibition rate is
different in seven anticancer drugs, and different drug have
different resistance rate. Chemotherapy guided by drug sus-
ceptibility test shows that the tumor response rates, includ-
ing the changes of AFP, OS, and second-stage-resection,
were superior in experimental group than that of control
group, whereas the side effects were relatively small and the
survival rate was higher.
In the dual channel infusion chemotherapy under the guid-
ance of drug susceptibility test, regional chemotherapy has
better clinical benefit than systemic chemotherapy, provid-
ing us a useful way for patients’ treatment with primary liver
cancer. However, because there were cases in which we
failed to detect sensitive chemotherapy drugs in the experi-
mental group, more drugs should be tested in future studies.
Conclusion
The artery and portal vein pump transfusion chemotherapy
guided by drug sensitive test was efficient for HCC treat-
ment. The patients can get longer OS and lower complica-
tion incidence.
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